1. Single-molecule systems for the detection and monitoring of plasma-circulating nucleosomes and oncoproteins in diffuse midline glioma.
- Author
-
Erez N, Furth N, Fedyuk V, Wadden J, Aittaleb R, Adam T, Schwark K, Niculcea M, Miclea M, Mody R, Franson A, Parmar HA, Ibrahim M, Lau B, Eze A, Nourmohammadi N, Fried I, Nazarian J, Ron G, Venneti S, Koschmann C, and Shema E
- Subjects
- Humans, Biomarkers, Tumor blood, Biomarkers, Tumor genetics, Single Molecule Imaging methods, Female, Male, Tumor Suppressor Protein p53 genetics, Adult, Mutation genetics, Epigenesis, Genetic, Nucleosomes metabolism, Nucleosomes genetics, Glioma blood, Glioma genetics, Glioma diagnosis, Glioma pathology, Histones genetics, Histones blood, Circulating Tumor DNA genetics, Circulating Tumor DNA blood, Brain Neoplasms genetics, Brain Neoplasms blood, Brain Neoplasms diagnosis, Brain Neoplasms pathology
- Abstract
The analysis of cell-free tumor DNA (ctDNA) and proteins in the blood of patients with cancer potentiates a new generation of non-invasive diagnostic approaches. However, confident detection of tumor-originating markers is challenging, especially in the context of brain tumors, where these analytes in plasma are extremely scarce. Here, we apply a sensitive single-molecule technology to profile multiple histone modifications on individual nucleosomes from the plasma of patients with diffuse midline glioma (DMG). The system reveals epigenetic patterns unique to DMG, significantly differentiating this group of patients from healthy subjects or individuals diagnosed with other cancer types. We further develop a method to directly quantify the tumor-originating oncoproteins, lysine 27 to methionine substitution in histone H3 (H3-K27M) and mutant p53, from <1 mL of plasma, allowing for the accurate molecular classification of patients with DMG. We show that our strategy correlates with MRI and droplet-digital PCR (ddPCR) measurements of ctDNA, highlighting the clinical potential of single-molecule-based, multi-parametric assays for DMG diagnosis and treatment monitoring., Competing Interests: Declaration of interests Yeda Research and Development Co., Ltd. have filed a provisional patent application related to aspects of this publication, and E.S. is named as an inventor. E.S. is also an inventor on an additional patent application related to this work (US2016/047747) and serves as a consultant for the company SeqLL, Inc., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2025
- Full Text
- View/download PDF